Serotonin syndrome
- Overview
- Theory
- Diagnosis
- Management
- Follow up
- Resources
Treatment algorithm
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups: see disclaimer
severe serotonin toxicity
emergency supportive care
This is a medical emergency and the patient needs to be treated in a critical care area.
Initial assessment of airway, breathing, and circulation should be undertaken and hyperthermia treated with rapid cooling depending on the patient's temperature.[2]Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ. 2014;348:g1626 http://www.ncbi.nlm.nih.gov/pubmed/24554467?tool=bestpractice.com [3]Isbister GK, Buckley NA. The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clin Neuropharmacol. 2005;28:205-214. http://www.ncbi.nlm.nih.gov/pubmed/16239759?tool=bestpractice.com
In the majority of patients it is best to sedate, intubate, and ventilate early, including induction of muscle paralysis to treat spontaneous clonus and hyperthermia. Sedation can be achieved either with morphine and midazolam or with propofol, avoiding fentanyl. Propofol allows for a more rapid wake-up afterwards compared with morphine and midazolam. Advice from a Poison Centre is essential, poison centres may differ between countries and regions.
activated charcoal
Additional treatment recommended for SOME patients in selected patient group
If severe serotonin toxicity is a result of an overdose, then decontamination with a single dose of activated charcoal may be considered if the overdose occurred within the last 2 hours.
Primary options
activated charcoal: 25-100 g orally as a single dose
chlorpromazine or cyproheptadine
Additional treatment recommended for SOME patients in selected patient group
Although there is limited evidence for the use of specific 5-HT antagonists in severe serotonin toxicity, intravenous chlorpromazine has been anecdotally successful.[25]Graham PM. Successful treatment of the toxic serotonin syndrome with chlorpromazine. Med J Aust. 1997;166:166-167. http://www.ncbi.nlm.nih.gov/pubmed/9059446?tool=bestpractice.com [27]Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol. 1999;13:100-109. http://www.ncbi.nlm.nih.gov/pubmed/10221364?tool=bestpractice.com
Hypotension due to peripheral alpha-antagonism must be avoided by pre-administration of intravenous fluids.
There is limited experience with chlorpromazine in this setting, and careful clinical judgement is required to determine whether there are adequate benefits versus the risk of hypotension.
For patients with neuromuscular excitation and agitation a single high dose of cyproheptadine (a non-specific 5-HT2 antagonist and antihistamine) may be used.[27]Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol. 1999;13:100-109. http://www.ncbi.nlm.nih.gov/pubmed/10221364?tool=bestpractice.com [28]Boddy R, Dowsett RP, Jeganathan D. Sublingual olanzapine for the treatment of serotonin syndrome (abstract). Clin Toxicol. 2006;44:426.[29]Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med. 1998;16:615-619. http://www.ncbi.nlm.nih.gov/pubmed/9696181?tool=bestpractice.com [30]Chan BS, Graudins A, Whyte IM, et al. Serotonin syndrome resulting from drug interactions. Med J Aust. 1998;169:523-525. http://www.ncbi.nlm.nih.gov/pubmed/9861909?tool=bestpractice.com For longer-acting serotonergic agents (e.g., fluoxetine), regular lower doses should be used. It also has sedative effects that are useful.
Primary options
chlorpromazine: consult specialist for guidance on dose
OR
cyproheptadine: consult specialist for guidance on dose
cessation of offending medication(s)
Additional treatment recommended for SOME patients in selected patient group
Once the patient has been stabilised, consideration should be given to stopping all serotonergic medications.
muscle paralysis and cooling
Treatment recommended for ALL patients in selected patient group
Rhabdomyolysis develops acutely in untreated, severe serotonin toxicity due to prolonged tonic-clonic muscle activity in association with hyperthermia. Characterised by a rising creatine phosphokinase level.
Can be prevented with early treatment of severe serotonin toxicity plus muscle paralysis and cooling.[24]Neuvonen PJ, Pohjola-Sintonen S, Tacke U, et al. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet. 1993;342:1419. http://www.ncbi.nlm.nih.gov/pubmed/7901695?tool=bestpractice.com [25]Graham PM. Successful treatment of the toxic serotonin syndrome with chlorpromazine. Med J Aust. 1997;166:166-167. http://www.ncbi.nlm.nih.gov/pubmed/9059446?tool=bestpractice.com [26]Power BM, Pinder M, Hackett LP, et al. Fatal serotonin syndrome following a combined overdose of moclobemide, clomipramine and fluoxetine. Anaesth Intensive Care. 1995;23:499-502. http://www.ncbi.nlm.nih.gov/pubmed/7485947?tool=bestpractice.com See Rhabdomyolysis.
moderate serotonin toxicity
cessation of offending medication(s) plus observation
All serotonergic drugs must be ceased.
Patients should be observed in hospital for at least 6 hours, although they are unlikely to develop severe or life-threatening toxicity.
Occasionally, severe serotonin toxicity may present early as moderate toxicity, such as with extended-release venlafaxine.[8]Isbister GK, Hackett LP, Dawson AH, et al. Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity. Br J Clin Pharm. 2003;56:441-450. http://onlinelibrary.wiley.com/doi/10.1046/j.1365-2125.2003.01895.x/full http://www.ncbi.nlm.nih.gov/pubmed/12968990?tool=bestpractice.com
If toxicity becomes life-threatening, patients should be treated as per guidelines for severe toxicity.
benzodiazepine or cyproheptadine
Additional treatment recommended for SOME patients in selected patient group
Benzodiazepines may be used to treat anxiety and also provide sedation.
For patients with neuromuscular excitation and agitation that is distressing or unpleasant, a single high dose of cyproheptadine (a non-specific 5-HT2 antagonist and antihistamine) may be used.[27]Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol. 1999;13:100-109. http://www.ncbi.nlm.nih.gov/pubmed/10221364?tool=bestpractice.com [28]Boddy R, Dowsett RP, Jeganathan D. Sublingual olanzapine for the treatment of serotonin syndrome (abstract). Clin Toxicol. 2006;44:426.[29]Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med. 1998;16:615-619. http://www.ncbi.nlm.nih.gov/pubmed/9696181?tool=bestpractice.com [30]Chan BS, Graudins A, Whyte IM, et al. Serotonin syndrome resulting from drug interactions. Med J Aust. 1998;169:523-525. http://www.ncbi.nlm.nih.gov/pubmed/9861909?tool=bestpractice.com For longer-acting serotonergic agents (e.g., fluoxetine), regular lower doses should be used. It also has sedative effects that are useful.
Primary options
diazepam: 5-10 mg orally as a single dose, may repeat in 30-60 minutes according to response
OR
cyproheptadine: consult specialist for guidance on dose
mild serotonin toxicity
cessation of offending medication(s) or dose reduction
No treatment is required in these patients, except ceasing the offending medication(s) or reducing the dose of the medication, if appropriate.[4]Dunkley EJ, Isbister GK, Sibbritt D, et al. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96:635-642. http://qjmed.oxfordjournals.org/content/96/9/635.full http://www.ncbi.nlm.nih.gov/pubmed/12925718?tool=bestpractice.com
Often, simple identification of the serotonergic symptoms may be sufficient, and continuation of the medication can then be decided on based upon the patient's tolerance of these effects and the benefits of treatment.
Choose a patient group to see our recommendations
Please note that formulations/routes and doses may differ between drug names and brands, drug formularies, or locations. Treatment recommendations are specific to patient groups. See disclaimer
Use of this content is subject to our disclaimer